Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with relapsed or refractory multiple myeloma (myeloma that has come back or stopped responding to treatment) according to recognised international guidelines.
• People whose doctors expect them to survive for more than 12 weeks.
• People who are reasonably physically active and able to carry out daily activities, based on a standard performance scale (scored 0, 1, or 2 out of 4).
• People whose myeloma cells show a certain protein called GPRC5D on more than 20% of their bone marrow plasma cells, confirmed by laboratory testing.
• People whose myeloma can be measured through at least one of the following: a specific protein (M protein) detected in the blood or urine at certain levels, abnormal free light chain levels in the blood, or a certain level of abnormal plasma cells found in the bone marrow.
• People who have already tried at least 3 prior rounds of treatment — including treatments from drug groups known as immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies — and whose myeloma has not responded, has come back within 12 months, or who could not tolerate the most recent treatment.

Who may not be able to join:

• People who have the "smoldering" (slow-growing, symptom-free) form of myeloma.
• People whose myeloma has only spread outside the bone marrow with no involvement inside it.
• People who have plasma cell leukaemia (a related but different blood cancer).
• People who also have a condition called amyloidosis at the same time.
• People whose cancer has spread to the brain or spinal fluid, or is pressing on the central nervous system.
• People who test positive for certain infections, including active hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus, based on specific blood test results.
• People who have had a significant allergic reaction or intolerance to any drug or ingredient that would be used in this study.
• People who have previously received any treatment that specifically targets the GPRC5D protein, such as certain antibodies, antibody-drug combinations, or CAR-T cell therapies.
• People who have had a stem cell transplant using their own cells within 8 weeks before the screening visit, or who are planning to have one during the study.
• People who have had an uncontrolled active infection requiring intravenous antibiotics, antiviral, or antifungal treatment within the 4 weeks before signing the consent form or before a cell collection procedure.
• People who have had major surgery within 28 days before the screening visit (routine biopsies and central line insertions are generally exceptions — confirm with trial site).
• People who have previously received a stem cell transplant using cells from another person (a donor).
• People who have other medical conditions or circumstances that, in the opinion of the treating doctor, may affect their ability to safely take part in the trial.
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.